BETHESDA, Md. — August 18, 2025 — Leads & Copy — Northwest Biotherapeutics (OTCQB:NWBO) announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. The company expressed its gratitude for Goldman’s dedication to the company, its shareholders, and cancer patients, extending condolences to his family. His duties will be assumed by other members of the management team.
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products for cancer treatment. Their lead program, DCVax®-L, targets glioblastoma (GBM), an aggressive brain cancer. The company has completed a Phase III trial of DCVax-L for GBM and submitted a MAA for commercial approval in the UK. They have also developed DCVax®-Direct for inoperable solid tumor cancers and plan to pursue Phase II trials this year.
Statements regarding future plans for DCVax® are forward-looking and subject to risks, including regulatory processes, third-party performance, product safety and efficacy, and the company’s ability to raise capital.
Contact:
Dave Innes
804-513-6758
dinnes@nwbio.com
Source: Northwest Biotherapeutics
